Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Spero Therapeutics, Inc. (SPRO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update"
05/11/2023 8-K Quarterly results
Docs: "Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update"
11/14/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/31/2022 8-K Quarterly results
Docs: "Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update"
11/10/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Spero Therapeutics, Inc. Condensed Consolidated Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Revenues: Grant revenue $ 2,356 $ 3,957 $ 12,698 $ 7,165 Collaboration revenue 708 38 2,814 $ 258 Total revenues 3,064 3,995 15,512 7,423 Operating expenses: Research and development 14,436 17,706 47,301 53,798 General and administrative 11,152 5,309 28,680 13,942 Total operating expenses 25,588 23,015 75,981 67,740 Loss from operations Other income 3 84 622 Net loss $ $ $ $ Deemed dividend $ — $ — $ — $ Net loss attributable to common shareholders of Spero Therapeutics, Inc. $ $ $ $ Net loss per share attributable to common shareholders per share, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and diluted: 32..."
08/05/2021 8-K Quarterly results
Docs: "Spero Therapeutics, Inc. Condensed Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenues: Grant revenue $ 3,042 $ 1,676 $ 10,342 $ 3,208 Collaboration revenue 2,106 51 2,106 $ 220 Total revenues 5,148 1,727 12,448 3,428 Operating expenses: Research and development 14,461 15,656 32,865 36,092 General and administrative 9,229 4,547 17,528 8,633 Total operating expenses 23,690 20,203 50,393 44,725 Loss from operations Other income 975 538 Net loss $ $ $ $ Deemed dividend $ — $ — $ — $ Net loss attributable to common shareholders of Spero Therapeutics, Inc. $ $ $ $ Net loss per share attributable to common shareholders per share, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and diluted: 29,675,399 20,..."
05/06/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Spero Therapeutics, Inc. Condensed Consolidated Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Revenues: Grant revenue $ 3,957 $ 4,471 $ 7,165 $ 10,471 Collaboration revenue 38 172 258 $ 4,046 Total revenues 3,995 4,643 7,423 14,517 Operating expenses: Research and development 17,706 18,495 53,798 40,047 General and administrative 5,309 4,133 13,942 11,803 Total operating expenses 23,015 22,628 67,740 51,850 Loss from operations Other income 84 268 622 1,394 Net loss $ $ $ $ Deemed dividend $ — $ — $ $ — Net loss attributable to common shareholders of Spero Therapeutics, Inc. $ $ $ $ Net loss per share attributable to common shareholders per share, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and dilut..."
08/06/2020 8-K Quarterly results
05/08/2020 8-K Quarterly results
03/16/2020 8-K Quarterly results
11/04/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15 of The Securities Exchange Act of 1934 Date of Report : November 4, 2019 SPERO THERAPEUTICS, INC. Delaware 001-38266 46-4590683 675 Massachusetts Avenue, 14 th Floor Cambridge, Massachusetts 02139 Registrant's telephone number, including area code: 242-1600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#...",
"Spero Therapeutics, Inc. Condensed Consolidated Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Revenues: Grant revenue $ 4,471 $ 658 $ 10,471 $ 2,274 Collaboration revenue 172 — 4,046 — Total revenues 4,643 658 14,517 2,274 Operating expenses: Research and development 18,495 8,459 40,047 24,758 General and administrative 4,133 3,134 11,803 9,238 Total operating expenses 22,628 11,593 51,850 33,996 Loss from operations Other income 268 472 1,394 659 Net loss attributable to common shareholders of Spero Therapeutics, Inc. $ $ $ $ Net loss per share attributable to common shareholders per share, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and diluted: 18,659,079 17,471,462 17,859,829 15,417,087 Spero The..."
08/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15 of The Securities Exchange Act of 1934 Date of Report : August 8, 2019 SPERO THERAPEUTICS, INC. Delaware 001-38266 46-4590683 675 Massachusetts Avenue, 14 th Floor Cambridge, Massachusetts 02139 Registrant's telephone number, including area code: 242-1600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#97...",
"Spero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update"
05/09/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15 of The Securities Exchange Act of 1934 Date of Report : May 9, 2019 SPERO THERAPEUTICS, INC. Delaware 001-38266 46-4590683 675 Massachusetts Avenue, 14 th Floor Cambridge, Massachusetts 02139 Registrant's telephone number, including area code: 242-1600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐...",
"Spero Therapeutics, Inc. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2019 2018 Revenues: Grant revenue $ 3,911 $ 1,153 Collaboration revenue 3,807 — Total revenues 7,718 1,153 Operating expenses: Research and development 9,526 8,925 General and administrative 3,888 3,044 Total operating expenses 13,414 11,969 Loss from operations Other income 624 172 Net loss attributable to common shareholders of Spero Therapeutics, Inc. $ $ Net loss per share attributable to common shareholders per share, basic and diluted $ $ Weighted average shares outstanding, basic and diluted: 17,221,120 14,369,182 Spero Therapeutics, Inc. Condensed Consolidated Balance Sheet Data March 31, 2019 December 31, 2018 Cash, cash equivalents and marketable securities $ 106,392 $ 115,443 O..."
03/14/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 14, 2019 SPERO THERAPEUTICS, INC. Delaware 001-38266 46-4590683 675 Massachusetts Avenue, 14 th Floor Cambridge, Massachusetts 02139 Registrant's telephone number, including area code: 242-1600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#9744...",
"Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review"
11/08/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 8, 2018 SPERO THERAPEUTICS, INC. Delaware 001-38266 46-4590683 675 Massachusetts Avenue, 14 th Floor Cambridge, Massachusetts 02139 Registrant's telephone number, including area code: 242-1600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#97...",
"Spero Therapeutics, Inc. Condensed Consolidated Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Grant revenue $ 658 $ 597 $ 2,274 $ 986 Operating expenses: Research and development 8,459 6,910 24,758 20,366 General and administrative 3,134 3,653 9,238 8,350 Total operating expenses 11,593 10,563 33,996 28,716 Loss from operations Other income 472 659 Net loss attributable to common stockholders of Spero Therapeutics, Inc. $ $ $ $ Net loss per share attributable to common stockholders per share, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and diluted: 17,471,462 335,285 15,417,087 333,402 Spero Therapeutics, Inc. Condensed Consolidated Balance Sheet Data September 30 2018 December 31, 2017 Cash, cash ..."
08/09/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 9, 2018 SPERO THERAPEUTICS, INC. Delaware 001-38266 46-4590683 675 Massachusetts Avenue, 14 th Floor Cambridge, Massachusetts 02139 Registrant's telephone number, including area code: 242-1600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#9744...",
"Spero Therapeutics Condensed Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Grant revenue $ 463 $ 249 $ 1,616 $ 389 Operating expenses: Research and development 7,374 7,457 16,299 13,456 General and administrative 3,060 2,957 6,104 4,697 Total operating expenses 10,434 10,414 22,403 18,153 Loss from operations Other income 15 402 187 1,590 Net loss attributable to common shareholders of Spero Therapeutics, Inc. $ $ $ $ Net loss per share attributable to common shareholders per share, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and diluted: 14,376,529 334,788 14,372,876 330,075 Spero Therapeutics Condensed Consolidated Balance Sheet Data June 30, 2018 December 31, 2017 Cash, cash equivalents and ma..."
05/10/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 10, 2018 SPERO THERAPEUTICS, INC. Delaware 001-38266 46-4590683 675 Massachusetts Avenue, 14 th Floor Cambridge, Massachusetts 02139 Registrant's telephone number, including area code: 242-1600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Spero Therapeutics, Inc. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2018 2017 Grant revenue $ 1,153 $ 140 Operating expenses: Research and development 8,925 5,999 General and administrative 3,044 1,740 Total operating expenses 11,969 7,739 Loss from operations Other income 172 469 Net loss attributable to common shareholders of Spero Therapeutics, Inc. $ $ Net loss per share attributable to common shareholders per share, basic and diluted $ $ Weighted average shares outstanding, basic and diluted: 14,369,182 330,075 Spero Therapeutics, Inc. Condensed Consolidated Balance Sheet Data March 31, December 31, 2018 2017 Cash, cash equivalents and marketable securities $ 75,393 $ 87,288 Other assets 5,666 6,191 Total assets $ 81,059 $ 93,479 Total liabilities ..."
04/02/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : April 2, 2018 SPERO THERAPEUTICS, INC. Delaware 001-38266 46-4590683 675 Massachusetts Avenue, 14 th Floor Cambridge, Massachusetts 02139 Registrant's telephone number, including area code: 242-1600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐...",
"Recent Clinical Highlights and Upcoming Milestones"
12/14/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 14, 2017 SPERO THERAPEUTICS, INC. Delaware 001-38266 46-4590683 675 Massachusetts Avenue, 14 th Floor Cambridge, Massachusetts 02139 Registrant's telephone number, including area code: 242-1600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#9...",
"Spero Therapeutics Condensed Consolidated Statement of Operations Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Revenue $ 597 $ — $ 986 $ — Operating expenses: Research and development 6,910 6,005 20,366 19,406 General and administrative 3,653 1,909 8,350 5,005 Total operating expenses 10,563 7,914 28,716 24,411 Loss from operations Other income : 504 2816 Net loss attributable to common stockholders of Spero Therapeutics, Inc. $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and diluted 335,285 318,948 333,402 307,852 Spero Therapeutics Condensed Consolidated Balance Sheet Data September 30, 2017 December 31, 2016 Cash, cash equivalents and investments $ 25,373 $ ..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy